A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation

Conditions:   Pancreatic Ductal Adenocarcinoma;   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of Head and Neck Interventions:   Biological: Durvalumab;   Biological: Oleclumab Sponsors:   University Health Network, Toronto;   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials